medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2023, Number 1

<< Back Next >>

Acta Med 2023; 21 (1)

Ultrasensitive C reactive protein as a proinflammatory marker and its association with obesity

Sánchez RPA, Seniscal ADA, Taracena PS, Ramírez FAK, Villanueva JV, Benítez BLF, Arias SPY, Díaz GEJ

Language: Spanish
References: 15
Page: 46-50
PDF size: 207.78 Kb.


ABSTRACT

Introduction: usCRP is an inflammatory biomarker produced in the liver. Obesity has been associated with a chronic inflammatory process and linked with said biomarker by overexpressing pro-inflammatory cytokines produced in adipose tissue. Objectives: study the association between elevated usCRP as a pro-inflammatory marker in patients with a diagnosis of obesity in the Mexican population. Material and methods: retrospective and cross-sectional study; registries of usCRP in patients of the preventive medicine clinic in a private hospital in Mexico City were reviewed from January to June 2019. The population included 672 patients, of which 419 were male and 253 female at least 20 years of age, in whom usCRP values < 10 mg/L. We performed a multiple linear regression with logarithmic transformations of usCRP, BMI, and sex. Results: the coefficient for the natural logarithm for the BMI was positive and statistically significant (p < 0.001), the coefficient for the male sex turned a negative and statistically significant result (p < 0.001), and the model obtained an R2 = 0.17. Conclusions: a positive association between elevated usCRP, female sex, and BMI were found; however, this model does not manage to explain all elevations in usCRP, meaning that we found elevations in both groups. More significant elevations were found in obese patients, with or without comorbidities, thus suggesting that usCRP is an inflammatory marker associated with obesity in Mexican population.


REFERENCES

  1. Organización Mundial de la Salud. Obesidad y sobrepeso [Internet]. Who.int. [citado en octubre del 2021]. 2021. Disponible en: https://who.int/es/news-room/fact-sheets/detail/obesity-and-overweight

  2. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019; 15 (5): 288-298. doi: 10.1038/s41574-019-0176-8.

  3. Encuesta Nacional de Salud y Nutrición (ENSANUT) 2018. México: Instituto Nacional de Salud Pública; 2018 [Internet]. Consultado en octubre 2018. Disponible en: https://ensanut.insp.mx/encuestas/ensanut2018/doctos/informes/ensanut_2018_presentacion_resultados.pdf

  4. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016; 22 Suppl 3: 1-203. doi: 10.4158/EP161365.GL.

  5. Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ. 2016; 115 (6): 317-321.

  6. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018; 9: 754. doi: 10.3389/fimmu.2018.00754.

  7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111 (12): 1805-1812. doi: 10.1172/JCI18921.

  8. Choi J, Joseph L, Pilote L. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes Rev. 2013; 14 (3): 232-244. doi: 10.1111/obr.12003.

  9. Ellulu MS, Khaza'ai H, Rahmat A, Patimah I, Abed Y. Obesity can predict and promote systemic inflammation in healthy adults. Int J Cardiol. 2016; 215: 318-324. doi: 10.1016/j.ijcard.2016.04.089.

  10. Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol. 2011; 55 (3): 660-665. doi: 10.1016/j.jhep.2010.12.017.

  11. Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. Am J Cardiol. 2010; 106 (1): 56-61. doi: 10.1016/j.amjcard.2010.02.017.

  12. Ridker PM. A test in context: high-sensitivity C-reactive protein. J Am Coll Cardiol. 2016; 67 (6): 712-723. doi: 10.1016/j.jacc.2015.11.037.

  13. Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis. 2017; 259: 75-82. doi: 10.1016/j.atherosclerosis.2017.02.003.

  14. Puri R, Nissen SE, Arsenault BJ, St John J, Riesmeyer JS, Ruotolo G et al. Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial. JAMA Cardiol. 2020; 5 (10): 1136-1143. doi: 10.1001/jamacardio.2020.2413.

  15. Farmer HR, Wray LA, Xian Y, Xu H, Pagidipati N, Peterson ED et al. Racial differences in elevated C-reactive protein among US older adults. J Am Geriatr Soc. 2020; 68 (2): 362-369. doi: 10.1111/jgs.16187.




2020     |     www.medigraphic.com